These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17395611)

  • 1. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
    Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
    Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
    Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
    Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
    Hirooka Y; Itoh A; Kawashima H; Hara K; Nonogaki K; Kasugai T; Ohno E; Ishikawa T; Matsubara H; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Yamamoto K; Kaneko T; Nieda M; Yokokawa K; Goto H
    Pancreas; 2009 Apr; 38(3):e69-74. PubMed ID: 19276867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
    Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
    Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
    Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
    J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
    Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
    Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
    Dauer M; Herten J; Bauer C; Renner F; Schad K; Schnurr M; Endres S; Eigler A
    J Immunother; 2005; 28(4):332-42. PubMed ID: 16000951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
    Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
    Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
    J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
    Smith PL; Yogaratnam Y; Samad M; Kasow S; Dalgleish AG
    Clin Transl Oncol; 2021 Jan; 23(1):110-121. PubMed ID: 32661823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
    Zhu XJ; Yang ZF; Zhou JY; Liu L; Sun XM; Fan ZF; Hu SY; Chen YC; Li WX; Cao M; Wang LX
    PLoS One; 2015; 10(7):e0132799. PubMed ID: 26181041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
    Schneider C; Schmidt T; Ziske C; Tiemann K; Lee KM; Uhlinsky V; Behrens P; Sauerbruch T; Schmidt-Wolf IG; Mühlradt PF; Schmidt J; Märten A
    Gut; 2004 Mar; 53(3):355-61. PubMed ID: 14960515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
    Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
    Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
    Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.
    De Sanctis F; Sandri S; Martini M; Mazzocco M; Fiore A; Trovato R; Garetto S; Brusa D; Ugel S; Sartoris S
    Vaccine; 2018 Jun; 36(25):3708-3716. PubMed ID: 29752021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model.
    Shangguan A; Shang N; Figini M; Pan L; Yang J; Ma Q; Hu S; Eresen A; Sun C; Wang B; Velichko Y; Yaghmai V; Zhang Z
    Cytotherapy; 2020 Jan; 22(1):6-15. PubMed ID: 32005355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer.
    Little EC; Wang C; Watson PM; Watson DK; Cole DJ; Camp ER
    J Surg Res; 2012 Aug; 176(2):359-66. PubMed ID: 22221605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
    Shevchenko I; Karakhanova S; Soltek S; Link J; Bayry J; Werner J; Umansky V; Bazhin AV
    Int J Cancer; 2013 Jul; 133(1):98-107. PubMed ID: 23233419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.